LVW Advisors LLC Has $341,000 Holdings in Glaukos Co. (NYSE:GKOS)

LVW Advisors LLC raised its stake in shares of Glaukos Co. (NYSE:GKOS) by 22.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,273 shares of the medical instruments supplier’s stock after purchasing an additional 413 shares during the period. LVW Advisors LLC’s holdings in Glaukos were worth $341,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in Glaukos during the third quarter worth $25,000. Harvest Fund Management Co. Ltd boosted its holdings in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV grew its stake in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares in the last quarter. EWA LLC purchased a new stake in shares of Glaukos in the third quarter valued at about $209,000. Finally, Procyon Advisors LLC bought a new position in shares of Glaukos during the third quarter valued at about $210,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GKOS has been the subject of several analyst reports. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and increased their price objective for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Truist Financial boosted their price objective on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler set a $140.00 target price on Glaukos in a research report on Thursday, October 17th. Finally, BTIG Research boosted their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $147.75.

Insider Activity at Glaukos

In related news, Director Gilbert H. Kliman sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,603 shares of company stock valued at $2,605,678. Corporate insiders own 6.40% of the company’s stock.

Glaukos Trading Up 0.1 %

Shares of GKOS stock opened at $156.60 on Tuesday. The stock has a market capitalization of $8.63 billion, a price-to-earnings ratio of -51.85 and a beta of 1.04. The company’s fifty day simple moving average is $146.21 and its two-hundred day simple moving average is $133.86. Glaukos Co. has a 1 year low of $83.90 and a 1 year high of $161.13. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) EPS. As a group, analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.